Chemistry:CHZ868
From HandWiki
CHZ868 is a drug which acts as a Janus kinase inhibitor selective for the JAK2 subtype. It was one of the first Janus kinase inhibitors developed, originally for the treatment of leukemia and related blood cancers, and while it did not get approved for clinical use, it is still used for research in the area.[1][2][3][4]
See also
References
- ↑ "CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms". Cancer Cell 28 (1): 15–28. July 2015. doi:10.1016/j.ccell.2015.06.006. PMID 26175413.
- ↑ "How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study". Scientific Reports 7 (1). August 2017. doi:10.1038/s41598-017-09586-3. PMID 28831147. Bibcode: 2017NatSR...7.9088K.
- ↑ "Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches". Blood Cancer Discovery 4 (5): 352–364. September 2023. doi:10.1158/2643-3230.BCD-22-0189. PMID 37498362.
- ↑ "Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable". Clinical Cancer Research 30 (3): 586–599. February 2024. doi:10.1158/1078-0432.CCR-23-0163. PMID 37992313.
 |  |
